Quality -of-life scores ( Piper Fatigue Scale MD 0.73 , 95 % CI 0.29 to 1.18 ; I2 = 0 % ; studies = 3 ) and peak oxygen consumption ( MD 2.77 mL/kg/min , 95 % CI -0.89 to 6.43 ; I2 = 36 % ; 2 studies , 32 participants ) were associated with very low- quality evidence , and we remain uncertain about the role of intravenous iron for these metrics .
Current evidence is insufficient to show benefit of intravenous iron preparations for the treatment of non-anaemic iron deficiency across a variety of patient population s , beyond stating that it may result in a small , clinical ly insignificant increase in haemoglobin concentration .
BACKGROUND Iron deficiency is one of the most common nutritional deficiencies , and has a number of physiological manifestations .
Early , or non-anaemic iron deficiency can result in fatigue and diminished exercise capacity .
Oral iron preparations have a high incidence of intolerable side effects , and are ineffective in certain forms of iron deficiency .
Consequently , intravenous iron preparations are increasingly used in the treatment of non-anaemic iron deficiency .
The newer , more stable iron preparations in particular purport to have a lower incidence of side effects , and are now used across a range of different patient population s. OBJECTIVES To assess the effects of intravenous iron therapy in the treatment of adults with non-anaemic iron deficiency .
Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial
Abstract Background : Compromised iron status is important in restless legs syndrome pathophysiology . We compared the efficacy and tolerability of ferric carboxymaltose ( single intravenous dose ) versus placebo for restless legs syndrome treatment in iron‐deficient nonanemic patients . Methods : Patients with moderate to severe restless legs syndrome and serum ferritin < 75 μg/L ( or serum ferritin 75‐300 μg/L and transferrin saturation < 20 % ) were r and omized to ferric carboxymaltose ( 1000 mg iron ) or placebo . Mean change difference between ferric carboxymaltose and placebo in International Restless Legs Syndrome Severity Scale score from baseline to week 4 was the primary end point ; week 12 was a secondary end point . Results : Ferric carboxymaltose treatment ( n = 59 ) led to nonsignificant improvement over placebo ( n = 51 ) in International Restless Legs Syndrome Severity Scale score at week 4 ( difference [ 95 % confidence interval ] , ‐2.5 [ ‐5.93 to 1.02 ] , P = 0.163 ) , reaching significance by week 12 ( ‐4.66 [ ‐8.59 to ‐0.73 ] , P = 0.021 ) . Conclusions : In patients who responded to treatment , ferric carboxymaltose may require more time to stabilize restless legs syndrome than previously assumed . © 2017 The Authors . Movement Disorders published by Wiley Periodicals , Inc. on behalf of International Parkinson and Movement Disorder Society
Quality -of-life scores ( Piper Fatigue Scale MD 0.73 , 95 % CI 0.29 to 1.18 ; I2 = 0 % ; studies = 3 ) and peak oxygen consumption ( MD 2.77 mL/kg/min , 95 % CI -0.89 to 6.43 ; I2 = 36 % ; 2 studies , 32 participants ) were associated with very low- quality evidence , and we remain uncertain about the role of intravenous iron for these metrics .
Current evidence is insufficient to show benefit of intravenous iron preparations for the treatment of non-anaemic iron deficiency across a variety of patient population s , beyond stating that it may result in a small , clinical ly insignificant increase in haemoglobin concentration .
BACKGROUND Iron deficiency is one of the most common nutritional deficiencies , and has a number of physiological manifestations .
Early , or non-anaemic iron deficiency can result in fatigue and diminished exercise capacity .
Oral iron preparations have a high incidence of intolerable side effects , and are ineffective in certain forms of iron deficiency .
Consequently , intravenous iron preparations are increasingly used in the treatment of non-anaemic iron deficiency .
The newer , more stable iron preparations in particular purport to have a lower incidence of side effects , and are now used across a range of different patient population s. OBJECTIVES To assess the effects of intravenous iron therapy in the treatment of adults with non-anaemic iron deficiency .